Company Profile
Immatics Stock Price, News & Analysis
- Ticker:
- IMTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Germany with major U
Stock performance
9.42 USD (-3.58%)
Close
Last updated: August 6, 2026
1.37B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IMTX closed down 3.58% at $9.42. No new same-company headline was identified in the current news window.
Company overview
TCR-Based Solid Tumor Immunotherapy
Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules.
PRAME Franchise
The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers.
Anzu-cel
Anzu-cel is an autologous PRAME-directed cell therapy in the pivotal Phase 3 SUPRAME study and is intended to become Immatics’ first commercial product.
Next-Generation Programs
IMA203CD8 adds engineered CD8 signaling, while IMA402 is a PRAME TCR bispecific being studied alone and with checkpoint inhibition.
Target Discovery and Manufacturing
Immatics integrates immunopeptidomics-based target discovery with TCR engineering, cell manufacturing, and bispecific development to build multiple therapies against the same cancer target.
Future catalysts
Interim and final analyses from the Phase 3 SUPRAME study are expected to be triggered during 2026.
Phase 1 IMA203CD8 data in gynecologic cancers are scheduled for presentation at ASCO 2026.
Phase 1b data for IMA402, including initial checkpoint-inhibitor combination data, are expected in the second half of 2026.
A potential commercial launch of anzu-cel is planned for 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immatics (IMTX)?
Immatics (IMTX) most recently closed at 9.42 USD, a -3.58% move versus the previous session.
What is the market cap of Immatics (IMTX)?
Immatics currently has a market capitalization of 1.37B USD on BioPharmSignal.
What does Immatics do?
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules. PRAME Franchise The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers. Anzu-cel Anzu-cel is an autologous PRAME-directed cell therapy...
On which exchange is IMTX stock listed?
Immatics (IMTX) is associated with NASDAQ, Germany with major U, Biopharma.
What is TCR-Based?
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules.
Which conditions is Immatics targeting with TCR-Based?
Immatics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Immatics describe recent progress with TCR-Based?
Interim and final analyses from the Phase 3 SUPRAME study are expected to be triggered during 2026. Phase 1 IMA203CD8 data in gynecologic cancers are scheduled for presentation at ASCO 2026. Phase 1b data for IMA402, including initial checkpoint-inhibitor combination data, are expected in the second half of 2026. A potential commercial launch of anzu-cel is...
What is Solid?
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules.